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score to stratify patients with PCa into low-, intermediate-, and 
high-risk groups. Even within a given risk group, significant clinical 
heterogeneity remains, particularly for those with intermediate-risk 
PCa  (IRPCa).8,9 Biochemical recurrence  (BCR) rates following 
definitive primary treatment for IRPCa are variable, with 5-year 
rates ranging from 2% to 70%.10,11 Given this clinical heterogeneity, 
a uniform treatment paradigm is unlikely to be an optimal approach 
for IRPCa. The optimal treatment for IRPCa is controversial; radical 
surgery, brachytherapy, external beam radiotherapy, hormone 
suppression, and combinations of these modalities are all feasible 
treatment options.12 Recently, several investigators have reported 
the appropriateness of active surveillance  (AS) in select men 
with IRPCa, demonstrating favorable outcomes.13,14 Thus, there 
is a critical need for methods capable of precise risk stratification 
and identifying some patients in whom AS would be appropriate 
in patients with IRPCa. To address these issues, we investigated 
preoperative variables associated with favorable pathology and BCR 
after RARP in IRPCa.
INTRODUCTION
Prostate cancer (PCa) is the most common solid organ malignancy 
in men in many western countries including the United States 
and is the fifth most common in Korean males.1–3 PCa shows an 
extremely heterogeneous clinical course, ranging from indolent and 
organ-confined to aggressive, metastatic lethal disease, leading to 
the overtreatment of men with relatively indolent disease and the 
undertreatment of those with aggressive tumors.4,5 Consequently, there 
is a great need to accurately assess the tumor characteristics of PCa so 
that appropriate treatment options can be considered.
Currently, pathological analyses  (including clinical stage and 
tumor grade in biopsy as measured by the Gleason score) and serum 
prostate-specific antigen (PSA) levels are key determinants for risk 
assessment and therapeutic decision-making.6 However, none of the 
histological criteria or biomarkers reported to date show sufficient 
sensitivity or specificity for detecting, monitoring, and determining 
the prognosis of PCa. D’Amico et al.7 were the first to combine the 
use of preoperative PSA levels, clinical stage, and biopsy Gleason 
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MATERIALS AND METHODS
We retrospectively reviewed the data of 1086  patients who 
underwent robot-assisted radical prostatectomy (RARP) for PCa at 
Severance Hospital between January 2006 and December 2012. Of 
the total RARP cases, 19.6% of patients (n = 213) met the criteria of 
IRPCa according to the D’Amico classification, defined as clinical 
stage T2b or PSA levels between 10 and 20 or Gleason score of 7. 
Patients who received neo-adjuvant treatment (n = 8) or adjuvant 
radiotherapy (n  =  6, four patients also received neo-adjuvant 
treatment) were excluded. As a result, 203 subjects satisfied the 
final inclusion criteria.
RARP was carried out using our standardized extraperitoneal 
technique by a single surgeon (YDC).15 The study was carried out in 
agreement with applicable laws and regulations, good clinical practices, 
and ethical principles as described in the Declaration of Helsinki. The 
Institutional Review Board of the hospital approved the present study 
protocol (Approval number: 4-2014-0619). Favorable pathology was 
defined as a Gleason score ≤6 and organ-confined cancer as detected 
by surgical pathology. BCR was defined as two sequential PSA 
values ≥0.2 ng ml−1 after prostatectomy.
Continuous variables are shown as the median and IQR. 
Differences in variables with a continuous distribution across 
dichotomous categories were assessed using the Mann–Whitney 
U-test. The Fisher exact test was used to evaluate the association 
between categorical variables. PSAD was categorized into 
approximate quartiles within the nested subcohort, with the highest 
quartile assigned as the reference group. Survival analyses were 
conducted according to the Kaplan–Meier method, and survival 
characteristics were compared using the log-rank test. Univariate 
and multivariate Cox regression model was used to identify the 
independent prognostic factors for BCR following RARP. Variables 
of P < 0.1 on univariate analysis included in the multivariate analysis. 
Statistical significance was considered at P < 0.05, and all reported 
P  values are two-sided. Analysis was performed using SPSS 20.0 
software (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
Table 1 lists the baseline characteristics of the 203 IRPCa cases. The 
median prebiopsy PSA and PSAD were 7.92 (IQR 5.59–11.93) ng ml−1 
and 0.27  (IQR 0.19–0.38) ng ml−1 g−1, respectively. The majority of 
men had a biopsy Gleason score 7 (69.9%); of those, 65 patients had a 
primary Gleason pattern of 4.
After RARP, pathologic organ-confined disease was found in 
103 (50.7%) cases and Gleason scores ≤6, 3 + 4, 4 + 3, and ≥8 were 
found in 53  (26.1%), 76  (37.4%), 60  (29.6%), and 14  (6.9%) cases, 
respectively. Overall, 38 patients (18.7% of IRPCa cohort) had favorable 
pathology after RARP (Table 1).
Clinical variables associated with favorable pathology in patients 
with IRPCa
Preoperative PSAD and CAPRA score were significantly associated with 
favorable pathology after RARP (P = 0.017, P = 0.013, respectively). 
However, there were no significant differences among the favorable 
and unfavorable pathology groups with respect to other preoperative 
variables, including age, BMI, preoperative PSA, and clinical stage 
and grade (Table 2).
When PSAD was categorized into quartiles, the lower quartile 
PSAD group was associated with favorable pathology compared with 
the highest quartile PSAD group after adjusting for PSA, clinical 
stage, and biopsy Gleason score  (odds ratio, 5.42; 95% confidence 
interval [CI], 1.01–28.97; P = 0.048) (Table 3).
Prediction of BCR after radical prostatectomy in patients with IRPCa
During a median 37.8  (interquartile range 24.6–60.2) months of 
follow-up, 66  patients  (32.5% of the IRPCa cohort) experienced 
BCR and the majority of BCR (95.5%) were occurred in unfavorable 
pathology group. One- and 3-year BCR-free survival rates were 94.6% 
and 91.8% for patients with favorable pathology, whereas 78.9% and 
63.9% for patients with unfavorable pathology.
Kaplan–Meier analysis exhibits significantly different BCR-free 
survival by PSAD quartiles  (log-rank P = 0.003) (Figure 1). Table 4 
shows results from univariate and multivariate Cox proportion 
hazard analysis for prediction of BCR after RARP. In univariate 
analyses, lower preoperative PSA, PSAD, CAPRA score, LVI and 
positive surgical margins were associated with BCR after RARP. When 
multivariate analysis with PSAD, PSAD (hazard ratio [HR], 4.641; 95% 
Table 1: Baseline characteristics of patients and pathological outcomes 
on radical prostatectomy
Characteristics Value (range or percentage)
Baseline characteristics
Patients (n) 203
Follow-up period, months (median)a 37.8 (24.6–60.2)
Age, years (mean)a 65.0 (60.0–70.0)
BMI, kg m−2 (median)a 24.2 (22.4–25.6)
PSA, ng ml−1 (median)a 7.92 (5.59–11.93)
PSAD, ng ml−1 cm−3 (median)a 0.27 (0.19–0.38)
Biopsy Gleason score, n (%)
5 2 (1.0)
6 59 (29.1)
7 (3+4) 77 (37.9)
7 (4+3) 65 (32.0)
Clinical T stage, n (%)
T1c 93 (45.8)
T2a 73 (36.0)
T2b 37 (18.2)
Pathological outcomes, n (%)
High-grade PIN 120 (59.1)
Lymphovascular invasion 10 (4.9)
Perineural invasion 113 (59.1)
Gleason score, n (%)
5 1 (0.5)
6 52 (25.6)
7 (3+4) 76 (37.4)
7 (4+3) 60 (29.6)
8 9 (4.4)
9 5 (2.5)
Pathologic T stage, n (%)
T2a 25 (12.3)
T2b 13 (6.4)
T2c 65 (32.0)
T3a 88 (43.3)
T3b 9 (4.4)
T4 3 (1.5)
Positive surgical margin, n (%) 53 (26.1)
Favorable pathologyb, n (%) 38 (18.7)
aThe data are shown as mean or median (IQR); bFavorable pathology was defined as 
Gleason score ≤6 and organ-confined cancer as detected by surgical pathology. BMI: body 
mass index; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; 
PIN: prostatic intraepithelial neoplasia; IQR: interquartile range
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study, BCR-free survival rates were superior in men classified as 
intermediate-risk by clinical stage compared with those assigned 
by biopsy Gleason score or PSA level. Interestingly, comparing men 
who met only one intermediate-risk criterion with low-risk men, 
no significant differences were found in terms of 10-year BCR-free 
survival by clinical stage. These authors also found that the BCR-free 
survival rates also differed according to the number of intermediate-risk 
criteria. Additional clinical factors have been proposed for stratifying 
men with IRPCa, including the proportion of positive biopsy cores, 
pretreatment PSA velocity, and primary Gleason pattern.19–21 Series 
from the Mayo Clinic and Johns Hopkins University showed a 
statistically significant difference in biochemical and progression-free 
outcomes in patients with a total Gleason score of 7, when stratified 
according to primary Gleason pattern.22,23 Recently, Zumsteg et al.8 
proposed a new risk stratification system for patients with IRPCa 
treated with dose-escalated, external-beam radiation therapy. They 
defined unfavorable IRPCa as any intermediate-risk patient with a 
primary Gleason pattern of 4, percentage of positive biopsy cores 
greater than or equal to 50%, or multiple intermediate-risk factors. 
Despite being significantly more likely to receive ADT, patients 
classified with unfavorable IRPCa had worse BCR-free survival, local 
failure, distant metastases, and CSM than patients with favorable 
IRPCa. Similarly, our study cohorts showed heterogeneous pathologic 
outcomes. Although 18.7% of the entire cohort had a favorable outcome 
after radical prostatectomy, a significant proportion of patients showed 
a high-grade advanced stage of disease.
Table 2: Comparison of preoperative variables between pathologic 
favorable and unfavorable group after radical prostatectomy
Variables Favorable pathology P
Yes No
Patients, n (%) 38 (18.7) 165 (81.3)
Preoperative variables
Age, years (mean)a 63.9 (60.0–70.0) 65.3 (60.0–71.0) 0.252*
BMI, kg m−2 (median)a 24.5 (22.3–26.2) 24.2 (22.5–25.5) 0.310*
PSA, ng ml−1 (median)a 7.98 (4.70–11.56) 7.92 (6.03–11.98) 0.134*
PSAD, ng ml−1 cm−3 
(median)a
0.23 (0.12–0.30) 0.28 (0.21–0.39) 0.017*
Biopsy Gleason score, n (%)
5 0 (0.0) 2 (1.2) 0.549†
6 13 (34.2) 46 (27.9)
7 (3+4) 16 (42.1) 61 (37.0)
7 (4+3) 9 (23.7) 56 (33.9)
Clinical T stage, n (%)
T1c 13 (34.2) 80 (48.5) 0.129†
T2a 19 (50.0) 54 (32.7)
T2b 6 (15.8) 31 (18.8)
CAPRA score, n (%)
≤2 13 (36.1) 26 (17.2) 0.013†
3 15 (41.7) 45 (29.8)
4 4 (11.1) 29 (19.2)
5 3 (8.3) 28 (18.5)
≥6 1 (2.8) 23 (15.2)
aThe data are shown as mean or median (IQR). P values were obtained from 
the *Mann–Whitney U-test or †Fisher’s exact test. PSA: prostate-specific antigen; 
PSAD: prostate-specific antigen density; CAPRA: cancer of the prostate risk assessment; 
BMI: body mass index; IQR: interquartile range
Table 3: Prediction of favorable pathology according to PSAD category in patients with intermediate-risk prostate cancer
PSAD quartile (ng ml−1 cm−3) Patients (n) Favorable pathologya, n (%) Unfavorable pathology, n (%) OR (95% CI)b P
PSAD<0.19 45 13 (28.9) 32 (71.1) 5.42 (1.01–28.97) 0.048
0.19≤PSAD<0.27 51 9 (17.6) 42 (82.4) 2.27 (0.53–9.63) 0.269
0.27≤PSAD<0.38 55 10 (18.2) 45 (81.8) 2.12 (0.63–7.14) 0.225
PSAD≥0.38 52 6 (11.5) 46 (88.5) -
aFavorable pathology was defined as Gleason score ≤6 and organ-confined cancer as detected by surgical pathology; bORs were calculated by logistic regression analysis and adjusted 
for preoperative PSA (continuous), clinical stage (categorical) and biopsy Gleason score (categorical). PSAD: prostate-specific antigen density; CI: confidence interval; OR: odds ratio
CI, 1.109–19.417; P = 0.036), LVI  (HR, 3.734; 95% CI, 1.644–8.482; 
P = 0.002) and positive surgical margins (HR, 1.842; 95% CI, 1.108–3.061; 
P = 0.018) were independent predictors of BCR after RARP.
DISCUSSION
The current study investigated the preoperative variables of favorable 
pathology and the risk of BCR in patients with IRPCa. Our study 
showed that approximately 20% of patients with IRPCa had a favorable 
pathology as detected by final pathology. Preoperative PSAD was not only 
associated with favorable pathology, but also an independent predictor 
of BCR in patients with IRPCa after prostatectomy. PSAD might be an 
additional tool for stratifying men with IRPCa and identifying some 
patients in whom AS would be appropriate in this setting.
PCa shows an extremely heterogeneous clinical course, ranging 
from indolent and organ-confined to aggressive, metastatic lethal 
disease.16–18 Moreover, we acknowledge that patients in each risk 
group have significant clinical heterogeneity, particularly IRPCa.8,9 
The original research concerning within-group heterogeneity by 
Reese et  al.9 revealed heterogeneous pathologic and biochemical 
outcomes among men within a single NCCN risk group. In their 
Figure 1: Kaplan–Meier analysis of BCR-free survival categorized by PSAD 
quartiles in patients with IRPCa; Pairwise analysis, significant between 
PSAD < 0.19 versus 0.27 ≤ PSAD < 0.38 (P = 0.025), and between 
PSAD < 0.19 versus PSAD ≥ 0.38 (P < 0.001). BCR: biochemical recurrence; 
IRPCa: intermediate-risk prostate cancer.
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PSAD was initially introduced to improve the sensitivity and 
specificity of PSA testing for PCa screening.24 However, some groups 
have also examined the role of PSAD in predicting advanced pathology 
after radical prostatectomy or BCR after local treatment.25,26 PSAD has 
been adopted as criteria for AS in men with low-risk PCa. The NCCN 
and PRIAS AS protocols include PSAD as an inclusion criterion. 
Furthermore, a recent study showed that PSAD was associated with an 
upgraded Gleason score of the prostatectomy specimen.27,28 While it is 
well-known that PSAD is a useful tool for selecting candidates for AS 
and prediction of BCR after definitive treatment in low-risk disease, the 
prognostic implications of PSAD in IRPCa have not yet been sufficiently 
elucidated. Our results suggest the potential utility of PSAD in predicting 
the favorable pathology and the risk of recurrence after surgery in IRPCa.
Recently, several investigators have reported the appropriateness of 
AS in select men with IRPCa, demonstrating favorable outcomes.13,14 The 
UCSF group reported that selected men with intermediate-risk features 
be appropriate candidates for AS, and are not necessarily more likely 
to progress.29 Better risk assessment through emerging biomarkers and 
better integration of clinical predictors could discriminate significant 
from indolent tumors in men with IRPCa. PSAD might be an additional 
tool for appropriate selection for AS in IRPCa. Further prospective 
design is needed to confirm the clinical application of PSAD for AS and 
consequent oncologic safety assessment in intermediate-risk disease.
Our study has both strengths and limitations. It had a retrospective 
design, which means that there may have been some sampling bias. 
However, the RARP data originated at a single institution and a 
single surgeon, minimizing performance variability within groups 
and decreasing performance bias. In addition, current study cohort 
consisted entirely of men treated with RARP. Thus, the prognostic 
implications of PSAD in IRPCa patients treated with brachytherapy, 
external beam radiotherapy, hormone suppression, and combinations 
of these modalities should be validated in future studies.
CONCLUSIONS
PSAD is associated with favorable pathology and is an independent 
predictor of BCR in patients with IRPCa after surgery. PSAD might be 
an additional tool for sub-stratifying patients with IRPCa into different 
prognostic groups and identifying some patients in whom AS would 
be appropriate in this setting.
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